Evidence map›Paper›PMID 29436711›Full record

ArticleEuropean journal of immunology2018

Evidence for dispensability of protein kinase R in host control of tuberculosis.

Shashirekha Mundhra, Ruslana Bryk, Natalie Hawryluk, Tuo Zhang, Xiuju Jiang, Carl F Nathan

Open access · bronzeAbstract read
In one paragraph

Article in European journal of immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. RNA Sensing ofVaccines · 2020
    Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Shashirekha MundhraImmunology and Microbial Pathogenesis Program, Weill Graduate School of Medical Sciences of Cornell University, New York City, NY, USA.
Ruslana BrykDepartment of Microbiology & Immunology, Weill Cornell Medicine, New York City, NY, USA.
Natalie HawrylukCelgene Global Heath, San Diego, CA, USA.
Tuo ZhangGenomics Resources Core Facility, Weill Cornell Medicine, New York City, NY, USA.
Xiuju JiangDepartment of Microbiology & Immunology, Weill Cornell Medicine, New York City, NY, USA.
Carl F NathanImmunology and Microbial Pathogenesis Program, Weill Graduate School of Medical Sciences of Cornell University, New York City, NY, USA.
Cornell University · USBristol-Myers Squibb (Switzerland) · CHWeill Cornell Medicine · US

Funding

Targeting the Host to Treat TB: Inhibitors of Protein Kinase RR33AI105807 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI NATHAN, CARL FRANCIS · 2015 to 2017
$1.1M
Targeting the Host to Treat TB: Inhibitors of Protein Kinase RR21AI105807 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI NATHAN, CARL FRANCIS · 2013 to 2014
$394k
NIAID NIH HHS R21 AI105807NIAID NIH HHS R33 AI105807
6 · The paper itself

Abstract

Genetic deficiency of protein kinase R (PKR) in mice was reported to enhance macrophage activation in vitro in response to interferon-γ (IFNγ) and to reduce the burden of Mycobacterium tuberculosis (Mtb) in vivo (Wu et al. PloS One. 2012 7:e30512). Consistent with this, treatment of wild-type (WT) macrophages in vitro with a novel PKR inhibitor (Bryk et al., Bioorg. Med. Chem. Lett. 2011 21:4108-4114) also enhanced IFN-γ-dependent macrophage activation (Wu et al. PloS One. 2012 7:e30512). Here we show that co-treatment with IFN-γ and a new PKR inhibitor identified herein to be highly but not completely selective likewise induced macrophages to produce more reactive nitrogen intermediates (RNI) and tumor necrosis factor alpha (TNF-α) and less interleukin 10 (IL-10) than seen with IFN-γ alone. Unexpectedly, however, this new PKR inhibitor had a comparable effect on PKR-deficient macrophages. Retrospective investigation revealed that the PKR-deficient mice in (Wu et al. PloS One. 2012 7:e30512) had not been backcrossed. On comparing genetically matched PKR-deficient and WT mice, we saw no impact of PKR deficiency on macrophage activation in vitro or during the course of Mtb infection in vivo. In addition, although 129S1/SvImJ macrophage responses to IFN-γ were greater than those of C57BL/6J macrophages, PKR was not required to mediate the IFN-γ-dependent production of IL-10, RNI or TNF-α in either strain. Together the data cast doubt on PKR as a potential therapeutic target for tuberculosis.

Indexed as

AnimalsCells, CulturedeIF-2 KinaseFemaleInterferon-gammaInterleukin-10Macrophage ActivationMacrophagesMiceMice, Inbred C57BLMice, KnockoutMycobacterium tuberculosisReactive Nitrogen SpeciesTuberculosisTumor Necrosis Factor-alphaeIF-2 KinaseIFNG protein, mouseIL10 protein, mouseInterferon-gammaInterleukin-10protein kinase R, mouseReactive Nitrogen SpeciesTumor Necrosis Factor-alphaIFN-γMacrophagePKRTNF-αTuberculosis

Identifiers

PMID29436711
PMCPMC6361384
OpenAlexW2792775798

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.